OR-RADISYS
19.3.2020 09:02:04 CET | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today announced the global availability of the Radisys Engage Video Assistant (EVA), the world’s first app-less AI-powered 3-in-1 (video, voice, text) bot for digital customer interactions. The EVA empowers customer support, sales and marketing teams to significantly enhance the customer experience by delivering greater personalization that drives customer acquisition, retention, and satisfaction with the cost savings of automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005010/en/
Customers can access the EVA to interact visually with sales professionals, subject-matter-experts, brand ambassadors, brand influencers, and customer care agents – simply by dialing a regular customer support number, using a Video over LTE (ViLTE) capable 4G/LTE or 5G smartphone, or by clicking a link on the website with no download required. The EVA can also be integrated with mobile apps. EVA’s powerful AI engine determines the customer’s intent and delivers the right information, and when required it supports the transition of the bot interaction to live agents to ensure a consistent and seamless customer experience and the most cost-effective use of live agents.
As a white label solution, the EVA offers service providers a platform with flexible deployment options, either in-network or accessible from the cloud. It enables new revenue streams by providing Video Call Bot-as-a-Service for call centers, SMBs and large enterprise customers, and it can reduce contact centers’ costs by automating interactions – like how-to interactions or sophisticated troubleshooting – that are underserved by voice or text bots alone.
Key Takeaways
- Today’s technologies provide tools that can control and improve the digital customer experience by creating self-service customer engagement. However, while chatbots, voice-enabled digital assistants, and other similar automation technologies are enabling businesses to achieve cost-effective scalability and agility, they lack a human touch needed for a satisfactory customer experience.
- The Engage Video Assistant application allows service providers, call centers and businesses to:
- Humanize existing calls and interactive mobile or voice apps with video while maintaining an authentic visual brand persona.
- Create video FAQs for new product launches or common customer support issues.
- Enhance existing bots and cumbersome interactive voice response (IVR) solutions.
- Scale influencers and brand ambassadors to unprecedented levels through personalized customer interactions.
- Engage customers at their time of choice – day or night, weekday or holiday – with personalized video interactions.
- Engage Video Assistant is deployed by Reliance Jio, the world’s largest VoLTE service provider, serving 370 million subscribers in India and helping its business customers to enhance their customer service, reduce their customer support cost, and enhance agent productivity.
“Radisys’ app-less calling experience enables businesses and service providers to offer an unprecedented in-call experience to their customers,” said Alan Quayle, independent consultant and founder, TADHack and TADHack Summit. “Its ease of integration lowers customer support costs; and improves productivity by helping customers get what they need faster, with a personal touch.”
“Video is a proven way to create greater immersion, increase click-throughs, and convert connections to purchases,” said Al Balasco, vice president, communications solutions, Radisys. “Engage Video Assistant is the first digital engagement bot application to combine video, voice and text seamlessly to provide ubiquitous and customizable brand and customer service reach for B2B and B2C customer interactions anywhere, anytime.”
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
